Sienna Gestion Sells 9,627 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Sienna Gestion cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 95.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 495 shares of the biopharmaceutical company’s stock after selling 9,627 shares during the period. Sienna Gestion’s holdings in Regeneron Pharmaceuticals were worth $254,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at $31,000. Caitlin John LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $34,000. Traub Capital Management LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $38,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its position in Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on REGN. Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research note on Monday, March 2nd. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. HSBC initiated coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $255.00 price target on the stock. Finally, Canaccord Genuity Group increased their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Stock Down 0.7%

Shares of REGN opened at $759.82 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The stock has a market capitalization of $80.33 billion, a price-to-earnings ratio of 18.28, a price-to-earnings-growth ratio of 2.04 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The business’s 50 day simple moving average is $770.81 and its 200-day simple moving average is $689.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the firm posted $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 5,274 shares of company stock valued at $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.